New protein-design & engineering solution enables the first step in Dotmatics' end-to-end scientific intelligence vision—accelerating multimodal R&D with connected, data-driven workflows BOSTON, June ...

BOSTON, Aug. 6, 2024 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced a significant minority investment in BioGlyph, a ...

R&D software developer Dotmatics is rolling out a platform for discovering and developing therapeutic antibodies and proteins. It’s the first part of what the company describes will grow to become a ...

BioGlyph possesses proprietary technology and exceptional talent in the realm of MsAbs R&D focused on accelerating and improving the development of protein therapeutics. One of the fastest growing new ...